Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays < 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50<10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 96.00 | |
10 mg | In stock | $ 173.00 | |
25 mg | In stock | $ 337.00 | |
50 mg | In stock | $ 589.00 | |
100 mg | In stock | $ 811.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity. |
Targets&IC50 | EGFR:3 nM |
In vitro | Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50: 3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM) [1]. Falnidamol demonstrates antiproliferative activity in mitogenic assays performed with KB cells [2]. |
In vivo | Falnidamol (p.o.; 10 mg/kg/day; 16 days) completely suppressed tumor growth of human A431 xenografts with respective a T/C value of 15% after 2 weeks of treatment. Falnidamol (50 mg/kg/day for 2 weeks) results in dephosphorylation of the EGF receptor in A431 xenograft-bearing mice. With Falnidamol (p.o.; 10 mg/kg/day; 16 days), the C4h is 2222 nM and the C24h is 244 nM [2]. |
Animal Research | Animal Model: Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431, FaDu, or HN5 cells Dosage: 10 mg/kg Administration: p.o.; daily; 16 days Result: Completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment [2]. |
Synonyms | BIBX 1382 |
Molecular Weight | 387.84 |
Formula | C18H19ClFN7 |
CAS No. | 196612-93-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 28.8 mg/mL (74.3 mM), Sonification and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Falnidamol 196612-93-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR BIBX 1382 BIBX-1382 BIBX1382 inhibitor inhibit